GPCR: Oral amylin and GLP-1 agonists show strong weight loss and safety in early and extension trials

Positive clinical data show ACCG-2671 achieved 3.3% weight loss and strong target engagement in early trials, while aleniglipron delivered up to 16.2% weight loss at 72 weeks with favorable tolerability. Ongoing Phase 3 trials and additional studies are expected to further define their profiles.

Original document: Structure Therapeutics Inc. [GPCR] Press release — Sep. 8 2026